|
|
Dynamic Antibody IndustryPublished by: BCC Research Published: Aug. 1, 2005 - 251 Pages Table of ContentsINTRODUCTION STUDY GOAL AND OBJECTIVES CONTRIBUTION OF THE STUDY AND FOR WHOM STUDY SCOPE AND FORMAT METHODOLOGY INFORMATION SOURCES ANALYST'S CREDENTIALS RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS BCC ONLINE SERVICES DISCLAIMER SUMMARY Summary Table: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, THROUGH 2010 ($ MILLIONS) Summary Figure: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, 2002-2010 ($ MILLIONS) OVERVIEW DEFINITIONS THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS INTELLECTUAL PROPERTY ISSUES/PATENT LICENSING THE TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS AND POLYCLONAL ANTIBODY PRODUCTS DO NOT? VALUATION OF ANTIBODY PRODUCT SALES TECHNOLOGY OVERVIEW THE HAMA PROBLEM AND ITS RESOLUTION PHAGE DISPLAY AND POLYSOME DISPLAY DIRECTED EVOLUTION ANTIBODY CLASSES ANTIBODY FORMS IN PRODUCTS ABTIDES ANTIBODY CONJUGATES ANTISERUMS BISPECIFIC ANTIBODIES CAMOUFLAGED ANTIBODIES CHIMERIC ANTIBODIES FULLY HUMAN ANTIBODIES HUMANIZED ANTIBODIES PROGENITOR STEM CELLS SINGLE-CHAIN ANTIBODIES SYNTHETIC ANTIBODIES SOURCES OF MONCLONAL ANTIBODIES ON THE MARKET Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES THE SPECIAL CASE OF ENBREL ANTIBODY TECHNOLOGIES IN DEVELOPMENT AFFIBODIES DOMAIN ANTIBODIES NANOBODIES NEW DIRECTIONS IN ANTIBODY RESEARCH THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS) Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS) THE TRANSGENIC ADVANTAGE TRADITIONAL PRODUCTION METHODS MICROBIAL FERMENTATION MAMMALIAN CELL CULTURE Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES THE ENBREL SHORTAGE THE CRUNCH IN CAPACITY REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS PRODUCTION OF ANTIBODIES IN ANIMALS GOATS AS MONOCLONAL ANTIBODIES FACTORIES CHICKENS AS MONOCLONAL ANTIBODIES FACTORIES PRODUCTION OF ANTIBODIES IN PLANTS PLASTIDS TARGETING AND COMPARTMENTALIZING TRANSGENIC SEEDS FOR ANTIBODY STORAGE THE MARKET FOR TRANSGENICALLY PRODUCED ANTIBODY PRODUCTS Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS) Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS) PLANTIBODIES IN DEVELOPMENT Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE ANTI-RABIES ANTIBODIES CARORX CLOSTRIDIUM DIFFICILE TOXIN A AND TOXIN B OTHER THERAPEUTIC PLANTIBODIES IN DEVELOPMENT TECHNOLOGY ISSUES WITH PLANT-BASED HUMAN ANTIBODIES USING MONOCLONAL ANTIBODIES AS CARRIERS FOR CYTOTOXIC DRUGS CONTRACT MANUFACTURING MARKET FOR BIOPHARMACEUTICALS GROWING Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS) PRODUCTS THE MARKET FOR POLYCLONAL AND MONOCLONAL ANTIBODY DRUGS Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS) Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS) THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS THE MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) Sales by Technology Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS) Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS) Sales by Target Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS) THE U.S. MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS) Marketed Products Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET THE EUROPEAN MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS) Marketed Products Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET Avastin The Avastin Advantage New Medicare Reimbursement Law Supports Use of Avastin Bexxar Campath/MabCampath Erbitux Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES Herceptin Humira Mylotarg Orthoclone OKT3 Panorex Raptiva Remicade ReoPro Rituxan/MabThera Simulect Synagis Tysabri (formerly Antegren) Xolair Zenapax Zevalin First Radioimmunotherapeutic Drug Results of Trials Sales of Zevalin THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT ABT-874 AMG 108 AMG 162 AMG 714 Anti-CD20 Humanized Anticlonal Antibody Anti-Tac(Fv)-PE38 Immunotoxin Anti-TGF Beta Avastin CAL Campath Cantuzumab Mertansine CAT-192 Cimzia (formerly CDP-870) Cotara Eculizumab Erbitux Felvizumab Herceptin HuMax-CD4 HuMax-CD20 HuMax-EGFr HuMax-Inflam Humira HuN901-DM1 HuZAF IMMU-102 and IMMU-103 Lucentis LymphoStat-B M200 MDX-010 MDX-018 MDX-060 MDX-070 Mepolizumab MLN 02 MLN 1202 MLN 2704 Numax Nuvion Omnitarg Osidem OvaRex Panitumumab Pemtumomab Pexelizumab Pro70769 R1569 Remicade Rituxan/MabThera SGN-15 SGN-30 Synagis TheraCIM hR3 Trabio Tysabri Vitaxin Xolair Zenapax THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS IMMUNOGLOBULINS Intramuscular Products Intravenous Products NEW APPROACHES TO THE PRODUCTION OF HUMAN POLYCLONAL ANTIBODIES THE MARKET FOR THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) MARKETED PRODUCTS ATG-Fresenius S BabyBIG CytoGam Flebogamma Gamimune Gamunex Nabi-HB Octagam Rabies Immune Globulin RespiGam Tetanus Immune Globulin Vaccinia Immune Globulin Varicella-Zoster Immune Globulin WinRho SDF Rho(D) Immune Globulin Anti-Thymocyte Globulin Atgam Thymoglobulin Antitoxins and Antivenins CroFab DigiFab Diphtheria Antitoxin ViperTAb PRODUCTS IN DEVELOPMENT Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT Altastaph ATG-Fresenius S CytoFab Nabi-HB Intravenous Thymoglobulin WinRho SDF Early-Stage Products in Development IN VIVO DIAGNOSTIC ANTIBODY PRODUCTS Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS) MARKETED PRODUCTS CEA-Scan Humaspect LeukoScan MIBG MyoScint NeutroSpec OctreoScan ProstaScint Verluma PRODUCTS IN DEVELOPMENT Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT AFP-Scan Blood Tumor Antibody Diagnostics CEA-Scan LeukoScan LymphoScan NeutroSpec ProstaScint Tru-Scint AD Tru-Scint AG APPLICATIONS LEADING THERAPEUTIC INDICATIONS OF APPROVED MONOCLONAL THERAPEUTIC ANTIBODY PRODUCTS Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%) AUTOIMMUNE DISEASES Crohn's Disease Psoriasis Rheumatoid Arthritis Antibody Products on the Market for the Treatment of Autoimmune Diseases Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES Antibodies in Development for the Treatment of Autoimmune Diseases Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES CANCER U.S. Cancer Statistics Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED) Table 30 CANCER PREVALENCE RATES: U.S., 2000 Breast Cancer Colorectal Cancer Head and Neck Cancer Kidney Cancer Leukemias Liver Cancer Lung Cancer Malignant Melanoma NonHodgkin's Lymphoma Osteosarcoma Ovarian Cancer Pancreatic Cancer Prostate Cancer Stomach Cancer Antibody Products on the Market for the Treatment of Cancer Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER Antibodies in Development for the Treatment of Cancer Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS CARDIOVASCULAR DISEASES Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002 Percutaneous Transluminal Coronary Angioplasty Antibody Products on the Market for the Treatment of Cardiovascular Disease Antibodies in Development for the Treatment of Cardiovascular Diseases Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES INFECTIOUS DISEASES Cytomegalovirus Infection Hepatitis Respiratory Syncytial Virus Infection Antibodies on the Market for the Treatment of Infectious Diseases Antibodies in Development for the Treatment of Infectious Diseases Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES OPHTHALMIC DISEASES Macular Degeneration ORGAN TRANSPLANT REJECTION AND GRAFT-VERSUS-HOST DISEASE Organ Transplant Market Size Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004 Antibody Products on the Market for the Treatment of Organ Transplant Rejection Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION Antibodies in Development for Organ Transplant Rejection Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION Bone Marrow and Stem Cell Transplantation/Graft-Versus-Host Disease Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004 RESPIRATORY DISEASES Allergic Rhinitis and Asthma Antibody Products on the Market for the Treatment of Allergic Rhinitis and Asthma Antibodies in Development for the Treatment of Allergic Rhinitis and Asthma Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA OTHER THERAPEUTIC APPLICATIONS Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES DIAGNOSTIC IMAGING APPLICATIONS IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN DEVELOPMENT FOR SELECTED INDICATIONS Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS INDUSTRY STRUCTURE ORIGINATORS COMMERCIAL DEVELOPERS VENDORS MANUFACTURERS TECHNOLOGY INNOVATORS PRICING FORECASTS PARTNERSHIPS ABOUND Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004 THE REGULATORY ENVIRONMENT MARKET SHARE OF MONOCLONAL ANTIBODY PRODUCT MANUFACTURERS Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%) GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS COMPANY PROFILES ABGENIX, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS XenoMouse and XenoMax Technologies Technology Advantages CORPORATE STRATEGY AMGEN, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 44 AMGEN'S MONOCLONAL ANTIBODY PRODUCT PIPELINE CORPORATE STRATEGY BIOGEN IDEC, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC BUSINESS OVERVIEW PRODUCTS CORPORATE STRATEGY CORIXA CORP. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY CYTOGEN CORPORATION BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY GENENTECH, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES GENMAB A/S BUSINESS OVERVIEW PRODUCTS CORPORATE STRATEGY GENZYME CORPORATION BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 47 GENZYME'S MONOCLONAL ANTIBODY PRODUCT PIPELINE CORPORATE STRATEGY GTC BIOTHERAPEUTICS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS AND TECHNOLOGIES Monoclonal Antibodies (MAB) and Immunoglobulin (Ig) Fusion Proteins CORPORATE STRATEGY IMMUNOMEDICS, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 48 IMMUNOMEDICS' PRODUCT PIPELINE CORPORATE STRATEGY MEDAREX, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 49 MEDAREX'S PRODUCT PIPELINE CORPORATE STRATEGY MEDIMMUNE, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION LEADING PRODUCTS Table 50 MEDIMMUNE'S MONOCLONAL ANTIBODY PRODUCT PIPELINE CORPORATE STRATEGY MILLENNIUM PHARMACEUTICALS, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 51 MILLENNIUM'S MONOCLONAL ANTIBODY PRODUCT PIPELINE CORPORATE STRATEGY NABI BIOPHARMACEUTICALS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 52 NABI BIOPHARMACEUTICALS' PRODUCT PIPELINE CORPORATE STRATEGY PLANET BIOTECHNOLOGY, INC. BUSINESS OVERVIEW PRODUCTS AND TECHNOLOGY CaroRx RhinoRx DoxoRx PROTEIN DESIGN LABS BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 53 PROTEIN DESIGN LABS' MONOCLONAL ANTIBODY PRODUCT PIPELINE CORPORATE STRATEGY PROTHERICS PLC BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY SYMPHOGEN A/S BUSINESS OVERVIEW PRODUCTS Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES CORPORATE STRATEGY TRANXENOGEN, INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS AND TECHNOLOGY CORPORATE STRATEGY VIREXX MEDICAL CORPORATION BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY XOMA LTD. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS CORPORATE STRATEGY YM BIOSCIENCES INC. BUSINESS OVERVIEW FINANCIAL INFORMATION PRODUCTS Table 55 YM BIOSCIENCE'S PRODUCT PIPELINE CORPORATE STRATEGY LIST OF TABLES Summary Table: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, THROUGH 2010 ($ MILLIONS) Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS) Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS) Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS) Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS) Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS) Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS) Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS) Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS) Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS) Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS) Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED) Table 30 CANCER PREVALENCE RATES: U.S., 2000 Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002 Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004 Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004 Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004 Table 44 AMGEN'S MONOCLONAL ANTIBODY PRODUCT PIPELINE Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES Table 47 GENZYME'S MONOCLONAL ANTIBODY PRODUCT PIPELINE Table 48 IMMUNOMEDICS' PRODUCT PIPELINE Table 49 MEDAREX'S PRODUCT PIPELINE Table 50 MEDIMMUNE'S MONOCLONAL ANTIBODY PRODUCT PIPELINE Table 51 MILLENNIUM'S MONOCLONAL ANTIBODY PRODUCT PIPELINE Table 52 NABI BIOPHARMACEUTICALS' PRODUCT PIPELINE Table 53 PROTEIN DESIGN LABS' MONOCLONAL ANTIBODY PRODUCT PIPELINE Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES Table 55 YM BIOSCIENCE'S PRODUCT PIPELINE LIST OF FIGURES Summary Figure: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, 2002-2010 ($ MILLIONS) XXV Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS) Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS) Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS) Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS) Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%) Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%) AbstractINTRODUCTIONMonoclonal antibody drugs offer several advantages over other types of drugs. Technologically, antibodies exhibit amazing specificity that allows for a safe and targeted attack on disease-causing cells or compounds. The antibody itself may be used as a weapon or the antibody may serve as the vehicle to deliver a drug. Along with high specificity, monoclonal antibodies are effective in a broad range of diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation. Also of great importance is that antibodies are virtually never toxic. As of May 2005, there were 18 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 500 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 80 of these were in clinical trials. This BCC report provides detailed market analyses and industry trends. It quantifies and qualifies the emerging market for monoclonal and polyclonal antibody drugs and imaging products. Forecasts and trends are gleaned from industry sources as well as from considered assessments of available and emerging technologies. The study also examines strategies used by biotechnology companies and pharmaceutical firms to develop and market products in this explosive market sector. SCOPE OF STUDY The report contains:
METHODOLOGY The base year for this study is 2005. Figures are based on revenue figures at the manufacturers' level and are projected at 2005-dollar value; that is, inflation is not computed into the projection figures. Information to prepare this study was derived from information obtained from product managers, marketing strategists, research executives and others at leading pharmaceutical and biotechnology companies that compete in the market for antibody drugs and imaging diagnostics or which have products in development for this market. INFORMATION SOURCES The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from the business literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||